ELEVATE-RR 试验中阿可替尼对比伊布替尼治疗经治慢性淋巴细胞白血病的详细安全性特征
该事后分析基于 ELEVATE-RR 试验中 529 例经治慢性淋巴细胞白血病患者(阿可替尼 266 例,伊布替尼 263 例),评估常见 BTK 抑制剂相关不良事件及临床关注事件。伊布替尼组整体及房颤/房扑、高血压、出血的事件负担评分更高,因不良事件停药风险阿可替尼更低(HR 0.62,95%CI 0.41-0.93)。
要点
- 伊布替尼组任何级别腹泻、关节痛、尿路感染、背痛、肌肉痉挛、消化不良发生率更高,暴露校正发生率高出 1.5 至 4.1 倍。
- 阿可替尼组头痛和咳嗽发生率更高,暴露校正发生率分别高出 1.6 倍和 1.2 倍。
- 伊布替尼组任何级别房颤/房扑、高血压、出血发生率及暴露校正发生率更高(分别 2.0、2.8、1.6 倍),因不良事件停药风险阿可替尼更低(HR 0.62,95%CI 0.41-0.93)。
核心结论
- 基于事件的分析和不良事件负担评分显示,伊布替尼相比阿可替尼整体不良事件负担更高,尤其在房颤、高血压和出血方面。
研究设计与样本
- ELEVATE-RR 试验的事后分析,安全性分析纳入 529 例经治慢性淋巴细胞白血病患者(阿可替尼 n=266,伊布替尼 n=263)。
- 评估常见 BTK 抑制剂相关不良事件和选定的临床关注事件,计算总体及选定事件的不良事件负担评分。
主要发现
- 伊布替尼组任何级别腹泻、关节痛、尿路感染、背痛、肌肉痉挛、消化不良发生率更高,暴露校正发生率高出 1.5 至 4.1 倍。
- 阿可替尼组头痛和咳嗽发生率更高,暴露校正发生率分别高出 1.6 倍和 1.2 倍。
- 伊布替尼组任何级别房颤/房扑、高血压、出血发生率及暴露校正发生率更高(分别 2.0、2.8、1.6 倍);两组整体心脏事件(MedDRA 系统器官分类)和感染发生率相似。
- 因不良事件停药的风险阿可替尼更低(HR 0.62,95%CI 0.41-0.93)。
- 伊布替尼相比阿可替尼整体及房颤/房扑、高血压、出血的事件负担评分更高。
局限性
- 该分析为开放标签研究设计,可能影响更主观的不良事件报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ELEVATE-RR demonstrated noninferior progression-free survival and lower incidence of key adverse events (AEs) with acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia. We further characterize AEs of acalabrutinib and ibrutinib via post hoc analysis. Overall and exposure-adjusted incidence rate was assessed for common Bruton tyrosine kinase inhibitor-associated AEs and for selected events of clinical interest (ECIs). AE burden scores based on previously published methodology were calculated for AEs overall and selected ECIs. Safety analyses included 529 patients (acalabrutinib, n = 266; ibrutinib, n = 263). Among common AEs, incidences of any-grade diarrhea, arthralgia, urinary tract infection, back pain, muscle spasms, and dyspepsia were higher with ibrutinib, with 1.5- to 4.1-fold higher exposure-adjusted incidence rates. Incidences of headache and cough were higher with acalabrutinib, with 1.6- and 1.2-fold higher exposure-adjusted incidence rate, respectively. Among ECIs, incidences of any-grade atrial fibrillation/flutter, hypertension, and bleeding were higher with ibrutinib, as were exposure-adjusted incidence rates (2.0-, 2.8-, and 1.6-fold, respectively); incidences of cardiac events overall (the Medical Dictionary for Regulatory Activities system organ class) and infections were similar between arms. Rate of discontinuation because of AEs was lower for acalabrutinib (hazard ratio, 0.62; 95% confidence interval, 0.41-0.93). AE burden score was higher for ibrutinib vs acalabrutinib overall and for the ECIs atrial fibrillation/flutter, hypertension, and bleeding. A limitation of this analysis is its open-label study design, which may influence the reporting of more subjective AEs. Overall, event-based analyses and AE burden scores demonstrated higher AE burden overall and specifically for atrial fibrillation, hypertension, and hemorrhage with ibrutinib vs acalabrutinib. This trial was registered at www.clinicaltrials.gov as #NCT02477696.
引用
- Seymour JF, Byrd JC, Ghia P, et al. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023. PMID: 37390310. doi:10.1182/blood.2022018818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。